Download PDF
Thromb Haemost 1975; 33(02): 142-147
DOI: 10.1055/s-0038-1647831
Original Article
Schattauer GmbH

Symposium Standardizing the Control of Oral Anticoagulant Treatment

G. I. C Ingram
1   Department of Haematology, St. Thomas’ Hospital and Medical School, London, SE 1 7 EH
› Author Affiliations
Further Information

Publication History

Publication Date:
02 July 2018 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Bangham D. R, Biggs R, Brozović M, Denson K. W. E. Draft report of a collaborative study of two thromboplastins (including the use of common abnormal plasma). Thrombosis et Diathesis Haemorrhagica Suppl 1970; 40: 341
    PubMedGoogle Scholar
  • 2 Bangham D. R, Biggs R, Brozović M, Denson K. W. E. Calibration of five different thromboplastins, using fresh and freeze-dried plasma. Thrombosis et Diathesis Haemorrhagica 1973; 29: 228
    PubMedGoogle Scholar
  • 3 Barker N. W, Butt H. R, Allen E. V, Bollman J. L. The effect of 3,3’-methylenebis (4-hydroxycoumarin) on blood coagulation factors. Journal of the American Medical Association 1942; 118: 1003
    PubMedGoogle Scholar
  • 4 Biggs R. Report on the standardization of the one-stage prothrombin time for the control of anticoagulant therapy. In Hunter Wright, Koller Streuli. (eds.) Genetics and the Interaction of Blood Clotting Factors, Thrombosis et Diathesis Haemorrhagica 17 Suppl. p. 303 1965;
    PubMedGoogle Scholar
  • 5 Biggs R, Bangham D. R. Standardization of the one stage prothrombin time test for the control of anticoagulant therapy. Availability and use of thromboplastin reference preparations. British Medical Journal III: 470 1971;
    PubMedGoogle Scholar
  • 6 Biggs R, Denson K. W. E. Standardization of the one-stage prothrombin time for the control of anticoagulant therapy. British Medical Journal I: 84 1967;
    PubMedGoogle Scholar
  • 7 Bingham J. B, Meyer O. O, Pohle F. J. Studies on the hemorrhagic agent 3,3’-methylenebis (4-hydroxycoumarin). I. Its effect on the prothrombin and coagulation time of the blood of dogs and humans. American Journal of the Medical Sciences 1941; 202: 653
    PubMedGoogle Scholar
  • 8 Butt H. R, Allen E. V, Bollmann J. L. A preparation from spoiled sweet clover (3,3-methylene-bis-(4-hydroxycoumarin) which prolongs coagulation and prothrombin time of the blood. Proceedings of the Mayo Clinic 1941; 16: 388
    PubMedGoogle Scholar
  • 9 Campbell H. A, Link K. P. Studies on the hemorrhagic sweet clover disease. IV. The isolation and crystallization of the hemorrhagic agent. Journal of Biological Chemistry 1941; 138: 21
    PubMedGoogle Scholar
  • 10 Campbell H. A, Smith W. K, Roberts W. L, Link K. P. Studies on the hemorrhagic sweet clover disease. II. The bioassay of hemorrhagic concentrates by following the prothrombin level in the plasma of rabbit blood. Journal of Biological Chemistry 1941; 138: 1
    PubMedGoogle Scholar
  • 11 Denson K. W. E. An investigation of ‘Thrombotest’ and the preparation of a similar combined reagent. Journal of Medical Laboratory Technology 1961; 18: 257
    PubMedGoogle Scholar
  • 12 Eastham R. D. Improved control of long-term anticoagulant therapy. British Medical Journal II: 337 1968; a
    PubMedGoogle Scholar
  • 13 Eastham R. D. Improved control of long term anticoagulant therapy using the partial thromboplastin clotting time. Journal of Clinical Pathology 21: 539P 1968; b
    PubMedGoogle Scholar
  • 14 Hills M, Ingram G. I. C. Monitoring successive batches of British Comparative Thromboplastin. British Journal of Haematology 1973; 25: 445
    CrossrefPubMedGoogle Scholar
  • 15 Leck I, Thomson J. M, Poller L. Quality control trials in the national reference thromboplastin scheme. British Journal of Haematology 1973; 25: 453
    CrossrefPubMedGoogle Scholar
  • 16 Lehmann J. Försök till kuratev och profylaktisk behandlung av thromboser med ett ρer-os-preparat (3,3’-Methylen-di-(4-hydroxykumarin)). Svenska Läkartid-ningen 1942; 39: 73
    PubMedGoogle Scholar
  • 17 Link K. P. The discovery of dicumarol and its sequels. Circulation 1959; 19: 97
    CrossrefPubMedGoogle Scholar
  • 18 Loeliger E. A. Progress in the control of oral anticoagulation. Thrombosis et Diathesis Haemorrhagica 1972; 28: 109
    PubMedGoogle Scholar
  • 19 Loeliger E. A, Meuwisse-Braun J. B, MuIs H, Buitendijk F. J. K, Veltkamp J. J, Hemker H. C. Laboratory control of oral anticoagulants. Definition of therapeutic range in terms of different thromboplastin preparations. Thrombosis et Diathesis Haemorrhagica 1970; 23: 569
    PubMedGoogle Scholar
  • 20 Mayer G. A. Method for reliable determination of clotting time in whole blood. Canadian Medical Association Journal 1955; 72: 927
    PubMedGoogle Scholar
  • 21 Mayer G. A. Standard clotting time in the control of adequate anticoagulant therapy. In MacMillan R. L, Mustard J. F. (eds) Anticoagulants and Fibrinolysins. Pitman; London: p. 204 1961
    Google Scholar
  • 22 MIale J. B, Kent J. W. Standardization of the therapeutic range for oral anticoagulants based on standard reference plasmas. American Journal of Clinical Pathology 1972; 57: 80
    CrossrefPubMedGoogle Scholar
  • 23 MIale J. B, Kent J. W. Performance characteristics of reference thromboplastins. American Journal of Clinical Pathology 1973; 60: 453
    CrossrefPubMedGoogle Scholar
  • 24 MIale J. B, LaFond D. Prothrombin time standardization. Proposal of the Standards Committee College of American Pathologists, Subcommittee on Coagulation Reagents. American Journal of Clinical Pathology 1969; 52: 154
    PubMedGoogle Scholar
  • 25 Owren P. A. Thrombotest. A new method for controlling anticoagulant therapy. Lancet II: 754 1959;
    PubMedGoogle Scholar
  • 26 Owren P. A, Aas K. The control of dicumarol therapy and the quantitative determination of prothrombin and proconvertin. Scandinavian Journal of Clinical and Laboratory Investigation 1951; 3: 201
    CrossrefPubMedGoogle Scholar
  • 27 Poller L. The theory and practice of anticoagulant treatment. John Wright &Sons Ltd; Bristol: p. 134 Fig. 3, 4 1962
    Google Scholar
  • 28 Poller L. A national standard for anticoagulant therapy. Lancet I: 491 1967;
    PubMedGoogle Scholar
  • 29 Poller L. Anticoagulant control and standardization of coagulation reagents. Medical Laboratory Technology 1972; 29: 280
    PubMedGoogle Scholar
  • 30 Prandoni A, Wright I. The anticoagulants. Heparin and the dicoumarin 3. 3’-methylene-bis-(4-hydroxyeoumarin). Bulletin of the New York Academy of Medicine 1942; 18: 433
    PubMedGoogle Scholar
  • 31 Quick A. J. The prothrombin in hemophilia and in obstructive jaundice. Journal of Biological Chemistry 1935; 109: Plxxiii.
    PubMedGoogle Scholar
  • 32 Roderick L. M. 1929; The pathology of sweet clover disease in cattle. Journal of the American Veterinary Medical Association 74: 314
    PubMedGoogle Scholar
  • 33 Roderick L. M. A problem in the coagulation of the blood. "Sweet clover disease of cattle." American Journal of Physiology 1931; 96: 413
    PubMedGoogle Scholar
  • 34 Schofield F. W. A brief account of a disease in cattle simulating hemorrhagic septicemia due to feeding sweet clover. Canadian Veterinary Record 1922; 3: 74
    PubMedGoogle Scholar
  • 35 Schofield F. W. Damaged sweet clover. The cause of a new disease in cattle simulating hemorrhagic septicemia and blackleg. Journal of the American Veterinary Medical Association 1924; 64: 553
    PubMedGoogle Scholar
  • 36 Stahmann M.A, Huebner G. F, Link K. P. Studies on the hemorrhagic sweet clover disease. V. Identification and synthesis of the hemorrhagic agent. Journal of Biological Chemistry 1941; 138: 513
    PubMedGoogle Scholar